You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb) – Benitec Biopharma last week disclosed delays in its efforts to dose patients in a Phase I/IIa trial of its expressed RNAi-based hepatitis C treatment TT-034 and said that it is taking steps to speed subject enrollment.
GenomeWeb Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.
The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.
In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.
According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.